Literature DB >> 16698688

Ex vivo expanded umbilical cord blood T cells maintain naive phenotype and TCR diversity.

S Parmar1, S N Robinson, K Komanduri, L St John, W Decker, D Xing, H Yang, J McMannis, R Champlin, M de Lima, J Molldrem, A Rieber, M Bonyhadi, R Berenson, E J Shpall.   

Abstract

BACKGROUND: Umbilical cord blood (CB) is a promising source of hematopoietic stem cells for allogeneic transplantation. However, delayed engraftment and impaired immune reconstitution remain major limitations. Enrichment of donor grafts with CB T cells expanded ex vivo might facilitate improved T-cell immune reconstitution post-transplant. We hypothesized that CB T cells could be expanded using paramagnetic microbeads covalently linked to anti-CD3 and anti-CD28 Ab.
METHODS: CB units were divided into three fractions: (1) cells cultured without beads, (2) cells cultured with beads and (3) cells cultured with beads following CD3+ magnetic enrichment. All fractions were cultured for 14 days in the presence of IL-2 (200 IU/mL).
RESULTS: A mean 100-fold expansion (range 49-154) of total nucleated cells was observed in the CD3+ magnetically enriched fraction. Following expansion, CB T cells retained a naive and/or central memory phenotype and contained a polyclonal TCR diversity demonstrated by spectratyping. DISCUSSION: Our data provide evidence that naive and diverse CB T cells may be expanded ex vivo and warrant additional studies in the setting of human CB transplantation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16698688     DOI: 10.1080/14653240600620812

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  15 in total

1.  Interleukin-7 permits Th1/Tc1 maturation and promotes ex vivo expansion of cord blood T cells: a critical step toward adoptive immunotherapy after cord blood transplantation.

Authors:  Craig C Davis; Luciana C Marti; Gregory D Sempowski; Durairaj A Jeyaraj; Paul Szabolcs
Journal:  Cancer Res       Date:  2010-06-08       Impact factor: 12.701

2.  In Vitro Differentiation and Expansion of Intrathymic T Cell Progenitors from Human Umbilical Cord Blood-Derived CD34(+) Cells.

Authors:  Bo Sun; Sang-Bum Park; Ji-Won Jung; Kwang-Won Seo; Yong-Soon Lee; Kyung-Sun Kang
Journal:  Int J Stem Cells       Date:  2009-05       Impact factor: 2.500

3.  Ex vivo expansion and Th1/Tc1 maturation of umbilical cord blood T cells by CD3/CD28 costimulation.

Authors:  Melissa A Mazur; Craig C Davis; Paul Szabolcs
Journal:  Biol Blood Marrow Transplant       Date:  2008-10       Impact factor: 5.742

Review 4.  Adoptive immunotherapy with the use of regulatory T cells and virus-specific T cells derived from cord blood.

Authors:  Patrick J Hanley; Catherine M Bollard; Claudio G Brunstein
Journal:  Cytotherapy       Date:  2015-01-24       Impact factor: 5.414

5.  Safety and feasibility of virus-specific T cells derived from umbilical cord blood in cord blood transplant recipients.

Authors:  Allistair A Abraham; Tami D John; Michael D Keller; C Russell N Cruz; Baheyeldin Salem; Lauren Roesch; Hao Liu; Fahmida Hoq; Bambi J Grilley; Adrian P Gee; Hema Dave; David A Jacobsohn; Robert A Krance; Elizabeth J Shpall; Caridad A Martinez; Patrick J Hanley; Catherine M Bollard
Journal:  Blood Adv       Date:  2019-07-23

6.  T-lymphocyte recovery and function after cord blood transplantation.

Authors:  Paul Szabolcs
Journal:  Immunol Res       Date:  2011-04       Impact factor: 2.829

7.  FOXP3 is a direct target of miR15a/16 in umbilical cord blood regulatory T cells.

Authors:  X Liu; S N Robinson; T Setoyama; S S Tung; L D'Abundo; M Y Shah; H Yang; E Yvon; N Shah; H Yang; M Konopleva; G Garcia-Manero; I McNiece; K Rezvani; G A Calin; E J Shpall; S Parmar
Journal:  Bone Marrow Transplant       Date:  2014-04-07       Impact factor: 5.483

8.  Third-party umbilical cord blood-derived regulatory T cells prevent xenogenic graft-versus-host disease.

Authors:  Simrit Parmar; Xiaoying Liu; Shawndeep S Tung; Simon N Robinson; Gabriel Rodriguez; Laurence J N Cooper; Hui Yang; Nina Shah; Hong Yang; Marina Konopleva; Jeffery J Molldrem; Guillermo Garcia-Manero; Amer Najjar; Eric Yvon; Ian McNiece; Katy Rezvani; Barbara Savoldo; Catherine M Bollard; Elizabeth J Shpall
Journal:  Cytotherapy       Date:  2013-10-26       Impact factor: 5.414

9.  Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes.

Authors:  Patrick J Hanley; Conrad Russell Young Cruz; Barbara Savoldo; Ann M Leen; Maja Stanojevic; Mariam Khalil; William Decker; Jeffrey J Molldrem; Hao Liu; Adrian P Gee; Cliona M Rooney; Helen E Heslop; Gianpietro Dotti; Malcolm K Brenner; Elizabeth J Shpall; Catherine M Bollard
Journal:  Blood       Date:  2009-05-14       Impact factor: 22.113

10.  CD3(+) and/or CD14(+) depletion from cord blood mononuclear cells before ex vivo expansion culture improves total nucleated cell and CD34(+) cell yields.

Authors:  H Yang; S N Robinson; J Lu; W K Decker; D Xing; D Steiner; S Parmar; N Shah; R E Champlin; M Munsell; A Leen; C Bollard; P J Simmons; E J Shpall
Journal:  Bone Marrow Transplant       Date:  2009-10-19       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.